Chen L - Search Results

1

Ellagitannins-Derived Intestinal Microbial Metabolite Urolithin A Ameliorates Fructose-Driven Hepatosteatosis by Suppressing Hepatic Lipid Metabolic Reprogramming and Inducing Lipophagy.

Zhang C, Song Y, Yuan M, Chen L, Zhang Q, Hu J, Meng Y, Li S, Zheng G, Qiu Z. Zhang C, et al. Among authors: chen l. J Agric Food Chem. 2023 Mar 8;71(9):3967-3980. doi: 10.1021/acs.jafc.2c05776. Epub 2023 Feb 24. J Agric Food Chem. 2023. PMID: 36825491

2

[Antidepressant effect of acute administration with Jianyate Hao (JYTH) and its possible mechanism].

Lv P, Li S, Wang RY, Chen L, Ku BS, Pan JC. Lv P, et al. Among authors: chen l. Zhongguo Zhong Yao Za Zhi. 2008 Feb;33(3):307-10. Zhongguo Zhong Yao Za Zhi. 2008. PMID: 18536473 Chinese.

3

Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.

Qiu Z, Zhang C, Zhou J, Hu J, Sheng L, Li X, Chen L, Li X, Deng X, Zheng G. Qiu Z, et al. Among authors: chen l. Mol Carcinog. 2019 Jan;58(1):31-41. doi: 10.1002/mc.22904. Epub 2018 Sep 20. Mol Carcinog. 2019. PMID: 30182439

4

Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.

Zhang C, Hu J, Sheng L, Yuan M, Wu Y, Chen L, Zheng G, Qiu Z. Zhang C, et al. Among authors: chen l. Toxicol Appl Pharmacol. 2019 Feb 15;365:51-60. doi: 10.1016/j.taap.2019.01.004. Epub 2019 Jan 6. Toxicol Appl Pharmacol. 2019. PMID: 30625338

5

Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.

Zhang C , Hu J , Sheng L , Yuan M , Wu Y , Chen L , Wang G , Qiu Z . Zhang C , et al. Among authors: chen l. Food Funct. 2019 Jun 19;10(6):3410-3420. doi: 10.1039/c9fo00284g. Food Funct. 2019. PMID: 31123744

6

Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.

Zhang C, Sheng L, Yuan M, Hu J, Meng Y, Wu Y, Chen L, Yu H, Li S, Zheng G, Qiu Z. Zhang C, et al. Among authors: chen l. Toxicol Appl Pharmacol. 2020 Apr 1;392:114918. doi: 10.1016/j.taap.2020.114918. Epub 2020 Feb 8. Toxicol Appl Pharmacol. 2020. PMID: 32045588

7

Preparation, Characterization, and In Vitro Pharmacodynamics and Pharmacokinetics Evaluation of PEGylated Urolithin A Liposomes.

Yi S, Zhang C, Hu J, Meng Y, Chen L, Yu H, Li S, Wang G, Zheng G, Qiu Z. Yi S, et al. Among authors: chen l. AAPS PharmSciTech. 2021 Jan 6;22(1):26. doi: 10.1208/s12249-020-01890-y. AAPS PharmSciTech. 2021. PMID: 33404864

8

Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway.

Zhang C, Zhou J, Hu J, Lei S, Yuan M, Chen L, Wang G, Qiu Z. Zhang C, et al. Among authors: chen l. RSC Adv. 2019 Jul 2;9(36):20624-20632. doi: 10.1039/c9ra00429g. eCollection 2019 Jul 1. RSC Adv. 2019. PMID: 35515542 Free PMC article.

9

Caffeine Ameliorates AKT-Driven Nonalcoholic Steatohepatitis by Suppressing De Novo Lipogenesis and MyD88 Palmitoylation.

Tan X, Sun Y, Chen L, Hu J, Meng Y, Yuan M, Wang Q, Li S, Zheng G, Qiu Z. Tan X, et al. Among authors: chen l. J Agric Food Chem. 2022 May 25;70(20):6108-6122. doi: 10.1021/acs.jafc.2c01013. Epub 2022 May 10. J Agric Food Chem. 2022. PMID: 35536225

10

Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.

Zhang C, Lu Y, Song Y, Chen L, Hu J, Meng Y, Chen X, Li S, Zheng G, Qiu Z. Zhang C, et al. Among authors: chen l, chen x. J Cell Mol Med. 2022 Jul;26(14):3995-4006. doi: 10.1111/jcmm.17435. Epub 2022 Jun 17. J Cell Mol Med. 2022. PMID: 35713152 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88,275 results

Search Page

Filters